In the entire cohort (n=294), patients receiving consolidation immunotherapy of PD-1-targeting ICIs (n=212, 72.1%) had a higher incidence of any-grade or grade 3–5 pneumonitis than those who received PD-L1-targeting ICIs (n=82, 27.9%), including any-grade pneumonitis (58.5% vs. 56.1%, p=0.913) and grade 3–5 pneumonitis (8.5% vs. 4.9%, p=0.291). The gene discussed is CD274; the disease is pneumonitis.